BRTX - BioRestorative Therapies, Inc. Stock Price and Quote

BRTX [NASD]

Index	-	P/E	-	EPS (ttm)	-12.48	Insider Own	17.90%	Shs Outstand	3.64M	Perf Week	-0.63%
Market Cap	12.25M	Forward P/E	-	EPS next Y	-3.63	Insider Trans	1.96%	Shs Float	2.90M	Perf Month	4.34%
Income	-34.60M	PEG	-	EPS next Q	-1.43	Inst Own	20.90%	Short Float / Ratio	1.57% / 0.07	Perf Quarter	5.03%
Sales	0.10M	P/S	122.53	EPS this Y	-30.60%	Inst Trans	3.52%	Short Interest	0.05M	Perf Half Y	7.56%
Book/sh	4.66	P/B	0.67	EPS next Y	33.30%	ROA	-171.20%	Target Price	10.50	Perf Year	-25.65%
Cash/sh	4.19	P/C	0.74	EPS next 5Y	-	ROE	-178.80%	52W Range	2.46 - 5.97	Perf YTD	13.82%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-47.62%	Beta	-
Dividend %	-	Quick Ratio	23.50	Sales past 5Y	-	Gross Margin	-	52W Low	27.24%	ATR	0.23
Employees	7	Current Ratio	23.50	Sales Q/Q	262.50%	Oper. Margin	-	RSI (14)	51.79	Volatility	5.59% 7.38%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	74.40%	Profit Margin	-	Rel Volume	0.07	Prev Close	3.11
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	619.71K	Price	3.13
Recom	2.00	SMA20	2.23%	SMA50	2.71%	SMA200	-1.07%	Volume	5,568	Change	0.64%

Mar-13-23 08:30AM	EXCLUSIVE: BioRestorative Seeks Expanded FDA Approval For BRTX-100 Clinical Application, Engages Advisory Firm Benzinga
07:00AM	BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100 GlobeNewswire
Mar-09-23 06:30AM	BRTXs ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome News Direct
Mar-07-23 06:30AM	BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023 GlobeNewswire -9.80%
Mar-02-23 09:00AM	EXCLUSIVE: BioRestorative To Receive Third US Patent For Metabolic ThermoStem Program Benzinga +29.39%
07:30AM	Loading…
07:30AM	BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program GlobeNewswire
Feb-10-23 08:45AM	BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes News Direct
Feb-08-23 09:00AM	BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program GlobeNewswire
08:30AM	EXCLUSIVE: BioRestorative Poised To Receive European Patent For ThermoStem Program Benzinga
Feb-03-23 09:25AM	BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results News Direct
Jan-26-23 08:30AM	2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies News Direct
Jan-17-23 09:29AM	BioRestorative Therapies to Present in The Jan 26th Virtual Investor Summit Microcap Event Newsfile -9.79%
Dec-06-22 07:00AM	BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication GlobeNewswire -6.61%
06:31AM	EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome Benzinga
Dec-05-22 07:00AM	BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease GlobeNewswire -5.33%
06:30AM	Loading…
06:30AM	EXCLUSIVE: BioRestorative Therapies Gets Exclusive License Rights From Regenexx For Development Of BRTX-100 Disc Program To Treat Chronic Lumbar Disc Disease Benzinga
Nov-29-22 11:20AM	BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022 GlobeNewswire +5.49%
Nov-16-22 08:56AM	BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022 GlobeNewswire
05:16AM	BioRestorative Therapies Third Quarter 2022 Earnings: US$1.28 loss per share (vs US$4.99 loss in 3Q 2021) Simply Wall St.
Nov-10-22 08:00AM	The NIH Has Given BioRestorative Therapies A Stamp Of Approval News Direct +8.77%
Oct-31-22 08:15AM	See Whats Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies! News Direct -5.03%
Oct-20-22 09:30AM	BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show GlobeNewswire
Oct-14-22 08:00AM	A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field News Direct
Sep-28-22 07:00AM	BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference GlobeNewswire +15.04%
Sep-27-22 07:00AM	BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference GlobeNewswire
Sep-07-22 07:00AM	BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 GlobeNewswire
Sep-01-22 09:00AM	Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst News Direct
Aug-25-22 03:49PM	Giving Metabolism A Boost? BioRestorative Uses Science Surrounding Brown Fat Cells To Provide A Possible Breakthrough In Metabolic Disorders News Direct +5.58%
Aug-24-22 06:30AM	EXCLUSIVE: BioRestorative Therapies Adds Additional Sites For Lumbar Disc Disease Trial Benzinga
Jun-30-22 07:30AM	BioRestorative Therapies Announces First Patient Enrolled for the Companys Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) GlobeNewswire -14.24%
07:30AM	Loading…
Jun-22-22 07:30AM	BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Companys Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) GlobeNewswire -12.43%
07:00AM	EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study Benzinga
Jun-13-22 07:00AM	BioRestorative Therapies Announces Clinical Site Initiation for the Companys Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD) GlobeNewswire -6.68%
Apr-29-22 08:00AM	BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease GlobeNewswire
Apr-18-22 08:00AM	BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease GlobeNewswire
Apr-04-22 08:00AM	BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification GlobeNewswire
Mar-10-22 08:00AM	BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program GlobeNewswire
Feb-16-22 08:30AM	BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program GlobeNewswire +13.65%
Feb-07-22 09:00AM	BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease Site Selection Underway GlobeNewswire
07:45AM	BioRestorative Therapies to Ring Nasdaq Stock Market Closing Bell GlobeNewswire
Feb-02-22 08:00AM	BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio GlobeNewswire -5.96%
Jan-26-22 06:00AM	BioRestorative Therapies Named One of Ten Most Innovative Regenerative Medicine Companies in 2022 by Insights Care Magazine GlobeNewswire
Jan-11-22 06:00AM	BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance GlobeNewswire +5.50%
Jan-06-22 06:00AM	BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference GlobeNewswire +8.56%
Jan-04-22 06:00AM	BioRestorative Therapies Awarded an STTR Phase I Grant to Explore the Therapeutic Effects of PEG-Peptide Hydrogel-Encapsulated Hypoxic Bone Marrow Stem Cells GlobeNewswire
Dec-22-21 07:28AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday InvestorPlace +17.51%
05:53AM	BioRestorative Stock Surges After Recruiting PRC Clinical As Partner For Lead Product Study Benzinga
Dec-21-21 04:01PM	BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease GlobeNewswire
06:00AM	BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show GlobeNewswire
Dec-20-21 06:00AM	BioRestorative Therapies, Inc. Releases Year-End Message GlobeNewswire
Dec-02-21 06:00AM	BioRestorative Therapies Announces Filing of Ten Patent Applications Related to its BRTX-100 Program GlobeNewswire
Nov-23-21 04:05PM	WISeKey, Luminaries21.com and OISTE.ORG Foundation signed a strategic agreement to launch high level NFTs for Good by WISe.ART with the support of 1090 worldwide leader members of Luminaries 21 GlobeNewswire
Nov-22-21 12:00PM	WISeKey Announces Full Year 2021 Revenue Guidance of $20 Million, an Increase of 32% as Compared to Full Year 2020 GlobeNewswire -9.93%
Nov-19-21 12:27PM	WISeKey Strengthens its Smart Card Reader Chips Business for Healthcare Applications and Renews Agreement with HID Global, an ASSA ABLOY Company GlobeNewswire
06:00AM	BioRestorative Therapies Enters into Letter of Intent with PRC Clinical GlobeNewswire
Nov-10-21 06:00AM	BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer GlobeNewswire
Nov-09-21 02:20PM	BioRestorative Therapies Announces Closing of $23 Million Public Offering GlobeNewswire +6.27%
Nov-04-21 09:21PM	BioRestorative Therapies Prices $23 Million Public Offering and Uplisting to the Nasdaq Capital Market GlobeNewswire
Oct-26-21 04:05PM	BioRestorative Therapies Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq GlobeNewswire -5.71%
08:00AM	BioRestorative Therapies Announces Nomination of Two New Members to the Board of Directors GlobeNewswire
Sep-23-21 09:00AM	BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program GlobeNewswire +9.23%
Sep-02-21 09:00AM	BioRestorative Therapies Receives Patent in Australia Related to its Off-the-Shelf ThermoStem® Program GlobeNewswire +31.25%
Aug-31-21 09:00AM	BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem® Program GlobeNewswire +6.58%
Aug-19-21 06:00AM	BioRestorative Therapies Awarded One of Top 10 Spine Device Companies by MedTech Outlook GlobeNewswire
Aug-11-21 08:30AM	BioRestorative Therapies Discusses Upcoming Annual Meeting of Stockholders GlobeNewswire
Aug-09-21 11:58AM	BioRestorative Therapies Announces Filing of Registration Statement for Proposed Public Offering GlobeNewswire +8.00%
Jun-07-21 07:00AM	CEO Presenting on the Emerging Growth Conference on June 9. Register here GlobeNewswire +13.92%

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Broadrick Dale	10% Owner	Feb 22	Buy	2.86	6,000	17,150	305,073	Mar 03 04:11 PM
ALSTODT LANCE	President, CEO, COB	Feb 01	Buy	3.10	400	1,241	187,321	Feb 02 02:49 PM
ALSTODT LANCE	President, CEO, COB	Jan 27	Buy	3.01	200	602	186,921	Jan 30 09:33 AM
ALSTODT LANCE	President, CEO, COB	Jan 20	Buy	3.13	200	627	186,721	Jan 24 12:27 PM
ALSTODT LANCE	President, CEO, COB	Jan 18	Buy	3.11	400	1,244	186,521	Jan 20 08:19 AM
ALSTODT LANCE	President, CEO, COB	Jan 09	Buy	3.08	100	308	186,121	Jan 10 06:06 PM
ALSTODT LANCE	President, CEO, COB	Dec 23	Buy	3.01	300	903	186,021	Dec 28 08:22 AM
ALSTODT LANCE	President, CEO, COB	Dec 07	Buy	2.99	1,800	5,375	185,721	Dec 07 06:04 PM
Broadrick Dale	10% Owner	Nov 30	Buy	2.77	200	555	299,073	Mar 03 04:11 PM
Silva Francisco	VP of Research and Development	Nov 21	Buy	2.62	943	2,467	166,046	Nov 21 05:14 PM
ALSTODT LANCE	President, CEO, COB	Nov 18	Buy	2.88	1,000	2,876	183,921	Nov 21 07:49 AM
Silva Francisco	VP of Research and Development	Oct 12	Buy	3.39	725	2,457	165,103	Oct 12 02:01 PM
Silva Francisco	VP of Research and Development	Oct 11	Buy	3.69	806	2,973	164,378	Oct 12 08:54 AM
Broadrick Dale	10% Owner	Sep 23	Buy	2.83	300	849	298,873	Sep 27 05:23 PM
ALSTODT LANCE	President, CEO, COB	Sep 22	Buy	2.92	200	584	182,921	Sep 23 09:55 AM
Silva Francisco	VP of Research and Development	Aug 29	Buy	3.21	2,816	9,048	163,572	Sep 09 06:17 PM
Silva Francisco	VP of Research and Development	Aug 29	Buy	3.32	307	1,019	12,136	Sep 09 06:17 PM
Silva Francisco	VP of Research and Development	Aug 26	Buy	3.35	2,600	8,710	160,756	Sep 09 06:17 PM
Silva Francisco	VP of Research and Development	Aug 26	Sale	3.39	3,958	13,410	158,156	Sep 09 06:17 PM
Broadrick Dale	10% Owner	Jul 13	Buy	3.00	200	600	298,573	Jul 15 11:46 AM
Broadrick Dale	10% Owner	Jul 12	Buy	2.97	900	2,673	298,373	Jul 15 11:46 AM
ALSTODT LANCE	President, CEO, COB	Jul 12	Buy	2.95	700	2,065	182,721	Jul 13 08:25 AM
Broadrick Dale	10% Owner	Jul 06	Buy	3.38	100	338	297,473	Jul 15 11:46 AM
Broadrick Dale	10% Owner	Jun 30	Buy	3.08	1,900	5,850	297,373	Jul 05 06:10 PM
ALSTODT LANCE	President, CEO, COB	Jun 30	Buy	3.10	1,100	3,408	182,021	Jul 01 09:20 AM
Broadrick Dale	10% Owner	Jun 21	Buy	3.68	100	368	295,473	Jun 23 03:42 PM
Broadrick Dale	10% Owner	Jun 17	Buy	3.80	600	2,282	295,373	Jun 23 03:42 PM
Broadrick Dale	10% Owner	Jun 16	Buy	3.81	2,000	7,611	294,773	Jun 17 05:05 PM
ALSTODT LANCE	President, CEO, COB	Jun 16	Buy	3.73	600	2,238	180,921	Jun 17 04:02 PM
Broadrick Dale	10% Owner	Jun 15	Buy	3.72	1,200	4,464	292,773	Jun 17 05:05 PM
ALSTODT LANCE	President, CEO, COB	Jun 15	Buy	3.68	700	2,578	180,321	Jun 15 05:30 PM
Kristal Robert Eugene	Chief Financial Officer	Jun 15	Buy	3.61	194	700	7,994	Jun 15 05:50 PM
ALSTODT LANCE	President, CEO, COB	Jun 14	Buy	3.91	500	1,956	179,621	Jun 15 11:01 AM
Broadrick Dale	10% Owner	Jun 13	Buy	3.92	1,300	5,097	291,573	Jun 15 04:45 PM
ALSTODT LANCE	President, CEO, COB	Jun 13	Buy	3.95	200	790	179,121	Jun 14 11:55 AM
Broadrick Dale	10% Owner	Jun 10	Buy	4.23	600	2,540	290,273	Jun 13 03:33 PM
Broadrick Dale	10% Owner	Jun 09	Buy	4.27	1,000	4,266	289,673	Jun 13 03:33 PM
Broadrick Dale	10% Owner	Jun 08	Buy	4.33	2,400	10,395	288,673	Jun 09 04:42 PM
ALSTODT LANCE	President, CEO, COB	Jun 08	Buy	4.28	100	428	178,921	Jun 09 11:41 AM
Broadrick Dale	10% Owner	Jun 07	Buy	4.72	3,600	17,003	286,273	Jun 09 04:42 PM
Kristal Robert Eugene	Chief Financial Officer	Jun 07	Buy	4.56	200	912	7,800	Jun 07 12:22 PM
Broadrick Dale	10% Owner	Jun 06	Buy	4.93	3,000	14,798	282,673	Jun 07 01:52 PM
Broadrick Dale	10% Owner	Jun 03	Buy	4.90	1,200	5,879	279,673	Jun 07 01:52 PM
Broadrick Dale	10% Owner	Jun 02	Buy	4.69	1,000	4,688	278,473	Jun 06 01:35 PM
Broadrick Dale	10% Owner	Jun 01	Buy	4.46	9,213	41,122	277,473	Jun 03 04:03 PM
ALSTODT LANCE	President, CEO, COB	Jun 01	Buy	4.60	200	920	178,821	Jun 03 06:58 AM
Broadrick Dale	10% Owner	May 27	Buy	3.61	10,957	39,592	268,260	Jun 01 04:30 PM
Broadrick Dale	10% Owner	May 26	Buy	3.51	4,950	17,364	259,303	May 31 05:18 PM
ALSTODT LANCE	President, CEO, COB	May 26	Buy	3.52	2,700	9,494	178,621	May 27 10:23 AM
Broadrick Dale	10% Owner	May 26	Sale	3.44	2,000	6,876	257,303	May 31 05:18 PM
ALSTODT LANCE	President, CEO, COB	May 02	Buy	3.95	400	1,579	175,921	May 02 05:14 PM
Kristal Robert Eugene	Chief Financial Officer	Apr 08	Buy	5.71	7,600	43,396	7,600	Apr 11 10:47 AM
Broadrick Dale	10% Owner	Apr 06	Buy	5.66	2,500	14,150	254,353	Apr 08 04:23 PM
Broadrick Dale	10% Owner	Apr 05	Buy	5.71	46,000	262,640	251,853	Apr 07 04:15 PM
Broadrick Dale	10% Owner	Mar 31	Buy	4.72	10,700	50,488	316,972	Apr 01 04:54 PM
Broadrick Dale	10% Owner	Mar 29	Buy	5.12	5,000	25,600	306,272	Apr 01 04:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience